Publication: Use of HIV postexposure prophylaxis in healthcare workers after occupational exposure: A Thai University Hospital setting
2
Issued Date
2006-07-27
Resource Type
ISSN
01252208
01252208
01252208
Other identifier(s)
2-s2.0-33746191791
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.89, No.7 (2006), 974-978
Suggested Citation
Sasisopin Kiertiburanakul, Bunchong Wannaying, Sirirat Tonsuttakul, Pranee Kehachindawat, Siriluk Apivanich, Somporn Somsakul, Kumthorn Malathum Use of HIV postexposure prophylaxis in healthcare workers after occupational exposure: A Thai University Hospital setting. Journal of the Medical Association of Thailand. Vol.89, No.7 (2006), 974-978. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/23683
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Use of HIV postexposure prophylaxis in healthcare workers after occupational exposure: A Thai University Hospital setting
Other Contributor(s)
Abstract
Background: PostExposure Prophylaxis (PEP) is widely used after exposures to Human Immunodeficiency Virus (HIV) to reduce the risk of infection in the healthcare setting. Few data are available on the safety and tolerability of Anti Retro Viral drugs (ARV) among Health Care Workers (HCWs) who are prescribed prophylaxis. Objective: To collect information about the safety and compliance of taking ARV for HIV PEP among HCWs. Material and Method: Retrospective review on registry data regarding occupational HIV exposures, the PEP regimens used, and the adverse events associated with PEP was performed. Results: During a five year-period, 820 episodes with occupational blood or body fluid exposures were reported. Nurses (27%) were the largest group at risk. The most common type of exposure was percutaneous injuries (82%). Only 125 (15%) HCWs had occupational exposures to HIV, 64 HCWs were prescribed HIV PEP and 32 (50%) HCWs did not complete the PEP regimen as initially prescribed. The commonly prescribed ARV was zidovudine (38%), lamivudine (33%), and indinavir (11%). Overall, 18 (28%) HCWs reported symptoms while on PEP, such as nausea (89%), vomiting (55%), and dizziness (39%). None of the HCWs had HIV seroconversion. Conclusions: Adverse effects from HIV PEP were very common. Clinicians prescribing HIV PEP need to discuss with HCWs about PEP efficacy and side effects. Education efforts aimed at occupational exposure prevention are still important issues.